Chronic lymphocytic leukemia Trials in Milan, Italy
Conditions / Chronic lymphocytic leukemia / Milan, Italy
Chronic lymphocytic leukemia has been the subject of sustained clinical investigation across multiple research sites.
68 total trials for this combination
Showing top 10 of 68 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06943872 | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | RECRUITING | — |
| NCT04666038 | Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | ACTIVE_NOT_RECRUITING | — |
| NCT01804686 | A Long-term Extension Study of PCI-32765 (Ibrutinib) | RECRUITING | PHASE3 |
| NCT05006716 | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | RECRUITING | — |
| NCT05006716 | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | RECRUITING | — |
| NCT04666038 | Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | ACTIVE_NOT_RECRUITING | — |
| NCT04965493 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | TERMINATED | PHASE1 |
| NCT00391066 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) | TERMINATED | PHASE2 |
| NCT05006716 | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | RECRUITING | — |